Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Duchenne muscular dystrophy (DMD) is an inherited, severe muscle wasting disease caused by the loss of the cytoskeletal protein, dystrophin. Patients usually die in their late teens or early twenties of cardiac or respiratory failure. We have previously demonstrated that the dystrophin related protein, utrophin is able to compensate for the loss of dystrophin in the mdx mouse, the mouse model of the disease. Expression of a utrophin transgene under the control of an HSA promoter results in localization of utrophin to the sarcolemma and prevents the muscle pathology. Here we show that the over-expression of full-length utrophin in a broad range of tissues is not detrimental in the mdx mouse. These findings have important implications for the feasibility of the up-regulation of utrophin in therapy for DMD since they suggest that tissue specific up-regulation may not be necessary.


Journal article


Neuromuscul Disord

Publication Date





713 - 721


Aging, Animals, Blotting, Western, Body Weight, Creatinine, Cytoskeletal Proteins, Disease Models, Animal, Disease Progression, Feasibility Studies, Gene Expression, Genetic Therapy, Homozygote, Immunohistochemistry, Membrane Proteins, Mice, Mice, Inbred mdx, Mice, Transgenic, Muscle, Skeletal, Muscular Dystrophy, Animal, Organ Specificity, Promoter Regions, Genetic, Tissue Distribution, Transgenes, Up-Regulation, Utrophin